Comparative one-month safety and effectiveness of five leading new-generation devices for transcatheter aortic valve implantation
Authors: Giordano Arturo , Corcione Nicola , Ferraro Paolo , Morello Alberto , Conte Sirio , Testa Luca , Bedogni Francesco , Iadanza Alessandro , Berti Sergio , Regazzoli Damiano , Romagnoli Enrico , Trani Carlo , Burzotta Francesco , Pepe Martino , Frati Giacomo , Biondi-Zoccai Giuseppe ,   The Registro Italiano GISE sull’impianto di Valvola Aortica Percutanea (RISPEVA) Study Investigators, Tamburino Corrado , Ettori Federica , Petronio Anna Sonia , Rinaldi Mauro , Klugmann Silvio , Rubino Paolo , Tremoli Elena , Marchese Alfredo , Sardella Gennaro , Pistis Gianfranco , Brscic Elvis , Giudice Pietro , Piatti Luigi , Ardissino Diego , Indolfi Ciro , Chiarella Francesco , Tespili Maurizio , De Servi Stefano , Bonmassari Roberto , Fappani Antonio , Cuccia Claudio , Cremonesi Alberto , Tomai Fabrizio 
Published: November 2019

Transcatheter aortic valve implantation (TAVI) for aortic stenosis is becoming an appealing alternative to surgical aortic valve replacement in high-risk patients and to medical therapy for inoperable ones. Several new-generation TAVI devices have been recently introduced, but comparative analyses are lacking. We aimed to compare 1-month outcomes associated with such five leading new-generation TAVI devices exploiting data collected in the prospective observational RISPEVA (Registro Italiano GISE sull’impianto di Valvola Aortica Percutanea) Study. We queried the dataset of the ongoing RISPEVA study to retrieve baseline, procedural and 1-month outcome details of patients undergoing TAVI with Acurate, Evolut, Portico, Lotus, and Sapien3. Analysis was based on unadjusted and propensity score-adjusted methods. We included 1976 patients, 234 (11.8%) treated with Acurate, 703 (35.6%) with Evolut, 151 (7.6%) with Lotus, 347 (17.6%) with Portico, and 541 (27.4%) with Sapien3. Unadjusted analysis for baseline features highlighted several significant differences, and other discrepancies were found for procedural features. Despite these differences, device and procedural success were similarly high (ranging from 98.0% to 99.4%, p > 0.05). However, procedural valve migration appeared more common with Acurate (p = 0.007), and major bleeding with Sapien3 (p = 0.002). Unadjusted analysis for 1-month outcomes also highlighted significant differences in the composite of death, stroke, myocardial infarction, major vascular complication, major bleeding, or renal failure (favoring Portico, p < 0.001), major vascular complications (favoring Lotus, p < 0.001), renal failure (favoring Portico, p = 0.035), and permanent pacemaker implantation (favoring Acurate, p < 0.001). Propensity score-adjusted analyses showed lower rates of major adverse events with Evolut and Portico (p < 0.05), major vascular complications with Lotus and Portico (p < 0.05), renal failure with Sapien3 (p < 0.05) and permanent pacemaker implantation with Acurate (p < 0.05). In conclusion, new-generation TAVI devices have different profiles of early comparative safety and efficacy. These findings should be taken into account for individualized decision making and patient management.